GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc covers the month of February 2025. The document serves as a transaction notification reporting changes in securities holdings by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The filing was signed on February 26, 2025.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific insider trading transactions involving American Depositary Shares (ADSs) and Ordinary Shares.
Material Changes and Transactions
The following transactions were reported for the period:
- Dr. Hal Barron (Non-Executive Director): Acquired 3,269.946 notional ADSs via dividend reinvestment in the Executive Supplemental Savings Plan on February 21, 2025, at $36.64 per ADS. Additionally, acquired 83 ADSs via dividend reinvestment in the 401(k) plan on the same date at $36.64 per ADS.
- James Ford (SVP and Group General Counsel): Acquired 60.846 notional ADSs via dividend reinvestment in the Executive Supplemental Savings Plan on February 21, 2025, at $36.64 per ADS. Separately, sold 10,400 Ordinary Shares on February 25, 2025, at £14.5541 per share on the London Stock Exchange.
- Emma Walmsley (Chief Executive Officer): Gifted 123,700 Ordinary Shares to a family member for nil consideration on February 21, 2025.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of insider transactions.
Investor Verification Checklist
- Verify the total share count changes for Dr. Hal Barron, James Ford, and Emma Walmsley in subsequent filings.
- Confirm the market price of GSK ADSs and Ordinary Shares on the transaction dates (Feb 21 and Feb 25, 2025) to validate the reported transaction prices.
- Review the nature of the "notional" ADS acquisitions to understand their impact on actual voting rights and economic exposure.
- Check for any related proxy statements or annual reports that may provide context on the dividend reinvestment plans mentioned.